Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...
Moderna now anticipates ending 2025 with cash and cash equivalents worth $8.1 billion, up from its previous forecast of ...
Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP operating expenses by $200 million since 3Q25 ...
SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...
The BioIndustry Association (BIA) has also announced its new CEO to replace Steve Bates, who stepped down last September to ...
Nvidia and Eli Lilly unveiled a co-innovation AI Lab for drug discovery efforts. Nvidia announced a strategic collaboration ...
Merck has other promising candidates in its late-stage pipeline, such as enlicitide decanoate/MK-0616, an oral PCSK9 ...
In a new letter, Noubar Afeyan, Ph.D., co-founder of Moderna and CEO of Flagship Pioneering, warns that these actions risk undermining the foundations of science itself to the ultimate detriment of ...
After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...
2don MSN
Health care roundup: Market talk
Health and Human Services Secretary Robert F. Kennedy Jr. on Tuesday reshaped the CDC’s powerful vaccine panel, naming two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback